Fulgent SWOT Analysis

The shift from COVID-19 testing peak (~$1.1B revenue in 2020 industry-wide COVID surge) to core genomic services has produced sharp yoy swings for Fulgent Genetics (NASDAQ: FLGT); COVID-era takedown left revenues down 60%+ vs peak and increased quarterly volatility. Core oncology and reproductive testing grew low- to mid-teens in 2024, but loss of high-margin emergency testing cut gross margin by ~8 percentage points and pressured adjusted EBITDA and the stock, which trades below 2019 highs. Investors watch if core segments can scale to replace prior ~$200–300M annual COVID-era contribution.

In oncology, Fulgent Genetics faces entrenched rivals like Foundation Medicine (Illumina) and Guardant Health with deeper clinical penetration and higher oncologist loyalty; Foundation reported $897M revenue in 2024, showing scale Fulgent lacks.

Shifting perception from a generalist genetic lab to a premier oncology specialist needs large marketing and clinical validation; 2024 R&D and SG&A trends show firms spend tens to hundreds of millions—Fulgent’s 2024 SG&A was $156M, highlighting the gap.

Surveys and adoption metrics indicate physician trust drives test selection; without focused KOL (key opinion leader) partnerships and peer‑reviewed oncology data, Fulgent risks slower uptake versus specialists with multi‑year real‑world evidence portfolios.

The global liquid biopsy market for cancer detection and minimal residual disease (MRD) is projected to grow from $1.8 billion in 2024 to about $8.5 billion by 2030, so Fulgent can use its high-throughput sequencing expertise to expand into early-stage screening and MRD monitoring.

Capturing even 5% of the 2030 market could add roughly $425 million in annual revenue, with MRD services offering recurring high-margin contracts for ongoing patient surveillance.

Success would diversify Fulgent’s mix away from episodic testing toward predictable, subscription-like revenue and improve margins, given diagnostics gross margins often exceed 60% in specialized assays.

With about $450 million in cash and equivalents as of FY2024 (10-K filed Feb 29, 2025), Fulgent can buy distressed biotech assets or niche tech firms to broaden its platform and IP portfolio.

Targeted deals could add specialized teams and established international customer bases—accelerating entry into markets like China or Europe where Fulgent seeks scale.

Industry consolidation in genomic testing (2024 deal count up ~18% YoY) lets Fulgent remove smaller rivals and immediately boost revenue and lab capacity.

The genetic testing market is crowded: Illumina, Invitae, and Myriad—each with 2024 revenues above $700M, $550M, and $700M respectively—use pricing and scale to defend share, squeezing smaller labs like Fulgent (FY2024 revenue $223M). Price wars on standard panels have pushed gross margins down industry-wide by ~5–8 percentage points since 2021, risking further margin erosion. Continuous innovation forces Fulgent to spend heavily on R&D—R&D was 9% of revenue in 2024—just to hold position, raising capital intensity and execution risk.

Potential FDA changes to Laboratory Developed Tests (LDTs) could raise compliance costs by an estimated 10–25% and add 6–18 months to product launches, squeezing Fulgent’s 2024 R&D cadence and margins.

Stricter pre-market review would advantage larger firms with regulatory teams, slowing Fulgent’s time-to-market and risking loss of market share in areas where it reported $789M revenue in 2024.

Regulatory uncertainty—no final rule by Jan 2026—creates a planning risk that may force higher reserves, delayed investments, and conservative guidance for future growth.